These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 34270794)

  • 1. Genome-wide association studies of toxicity to oxaliplatin and fluoropyrimidine chemotherapy with or without cetuximab in 1800 patients with advanced colorectal cancer.
    Watts K; Wills C; Madi A; Palles C; Maughan TS; Kaplan R; Al-Tassan NA; Kerr R; Kerr D; Gray V; West H; Houlston RS; Escott-Price V; Cheadle JP
    Int J Cancer; 2021 Nov; 149(9):1713-1722. PubMed ID: 34270794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy.
    Madi A; Fisher D; Maughan TS; Colley JP; Meade AM; Maynard J; Humphreys V; Wasan H; Adams RA; Idziaszczyk S; Harris R; Kaplan RS; Cheadle JP
    Eur J Cancer; 2018 Oct; 102():31-39. PubMed ID: 30114658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience.
    Adams RA; Meade AM; Madi A; Fisher D; Kay E; Kenny S; Kaplan RS; Maughan TS
    Br J Cancer; 2009 Jan; 100(2):251-8. PubMed ID: 19165196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Oxaliplatin/5-Fluorouracil/Capecitabine-Cetuximab Combination Therapy and Its Effects on K-Ras Mutations in Advanced Colorectal Cancer.
    Wei L; Chen J; Wen J; Wu D; Ma X; Chen Z; Huang J
    Med Sci Monit; 2020 Feb; 26():e919031. PubMed ID: 32062671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand-foot syndrome.
    Watts K; Wills C; Madi A; Palles C; Maughan TS; Kaplan R; Al-Tassan NA; Kerr R; Kerr DJ; Houlston RS; Escott-Price V; Cheadle JP
    Int J Cancer; 2022 Sep; 151(6):957-966. PubMed ID: 35467766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G).
    Sakai D; Taniguchi H; Sugimoto N; Tamura T; Nishina T; Hara H; Esaki T; Denda T; Sakamoto T; Okuda H; Satoh T; Tsushima T; Makiyama A; Tsuda T; Hosokawa A; Kuramochi H; Tokunaga S; Moriwaki T; Yasui H; Ishida H; Tsuji A; Otsu S; Shimokawa H; Baba E; Sato M; Matsumoto S; Ozaki Y; Shinozaki K; Tamagawa H; Goto M; Kadowaki S; Fujii H; Koh Y; Yamazaki K; Hironaka S; Kishimoto J; Boku N; Hyodo I; Muro K
    Eur J Cancer; 2020 Aug; 135():11-21. PubMed ID: 32526634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database.
    Wagner AD; Grothey A; Andre T; Dixon JG; Wolmark N; Haller DG; Allegra CJ; de Gramont A; VanCutsem E; Alberts SR; George TJ; O'Connell MJ; Twelves C; Taieb J; Saltz LB; Blanke CD; Francini E; Kerr R; Yothers G; Seitz JF; Marsoni S; Goldberg RM; Shi Q
    J Natl Cancer Inst; 2021 Apr; 113(4):400-407. PubMed ID: 32835356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study.
    Rothenberg ML; Cox JV; Butts C; Navarro M; Bang YJ; Goel R; Gollins S; Siu LL; Laguerre S; Cunningham D
    Ann Oncol; 2008 Oct; 19(10):1720-6. PubMed ID: 18550577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase II Study of XELOX and Cetuximab as First-Line Therapy in Patients With KRAS Wild Type Metastatic Colorectal Cancer (FLEET2 Study).
    Hazama S; Maeda H; Iwamoto S; Kim HM; Takemoto H; Kobayashi K; Sakamoto J; Nagata N; Oba K; Mishima H
    Clin Colorectal Cancer; 2016 Dec; 15(4):329-336. PubMed ID: 27507128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study.
    Soda H; Maeda H; Hasegawa J; Takahashi T; Hazama S; Fukunaga M; Kono E; Kotaka M; Sakamoto J; Nagata N; Oba K; Mishima H
    BMC Cancer; 2015 Oct; 15():695. PubMed ID: 26467662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab in Combination With Either FOLFOX-4 or XELOX-2 in First-line Treatment of Patients With Metastatic Colorectal Cancer: A Multicenter Randomized Phase II Trial of the Gruppo Oncologico dell'Italia Meridionale (GOIM 2802).
    Maiello E; Di Maggio G; Cordio S; Cinieri S; Giuliani F; Pisconti S; Rinaldi A; Febbraro A; Latiano TP; Aieta M; Rossi A; Rizzi D; Di Maio M; Colucci G; Bordonaro R
    Clin Colorectal Cancer; 2020 Jun; 19(2):109-115. PubMed ID: 32089455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
    Maughan TS; Adams RA; Smith CG; Meade AM; Seymour MT; Wilson RH; Idziaszczyk S; Harris R; Fisher D; Kenny SL; Kay E; Mitchell JK; Madi A; Jasani B; James MD; Bridgewater J; Kennedy MJ; Claes B; Lambrechts D; Kaplan R; Cheadle JP;
    Lancet; 2011 Jun; 377(9783):2103-14. PubMed ID: 21641636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
    Cassidy J; Clarke S; Díaz-Rubio E; Scheithauer W; Figer A; Wong R; Koski S; Lichinitser M; Yang TS; Rivera F; Couture F; Sirzén F; Saltz L
    J Clin Oncol; 2008 Apr; 26(12):2006-12. PubMed ID: 18421053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration.
    Fernandez-Rozadilla C; Cazier JB; Moreno V; Crous-Bou M; Guinó E; Durán G; Lamas MJ; López R; Candamio S; Gallardo E; Paré L; Baiget M; Páez D; López-Fernández LA; Cortejoso L; García MI; Bujanda L; González D; Gonzalo V; Rodrigo L; Reñé JM; Jover R; Brea-Fernández A; Andreu M; Bessa X; Llor X; Xicola R; Palles C; Tomlinson I; Castellví-Bel S; Castells A; Ruiz-Ponte C; Carracedo A;
    Pharmacogenomics J; 2013 Jun; 13(3):209-17. PubMed ID: 22310351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer.
    Doi T; Boku N; Kato K; Komatsu Y; Yamaguchi K; Muro K; Hamamoto Y; Sato A; Koizumi W; Mizunuma N; Takiuchi H
    Jpn J Clin Oncol; 2010 Oct; 40(10):913-20. PubMed ID: 20462981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
    Petrelli F; Labianca R; Zaniboni A; Lonardi S; Galli F; Rulli E; Rosati G; Corallo S; Ronzoni M; Cardellino GG; Mattioli R; Mambrini A; Ciuffreda L; Banzi M; Pusceddu V; Maiello E; Zampino M; Zagonel V; Marchetti P; Corsi D; Rimassa L; Cinieri S; Sobrero A
    JAMA Oncol; 2020 Apr; 6(4):547-551. PubMed ID: 32053133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized study comparing short-time infusion of oxaliplatin in combination with capecitabine XELOX(30) and chronomodulated XELOX(30) as first-line therapy in patients with advanced colorectal cancer.
    Qvortrup C; Jensen BV; Fokstuen T; Nielsen SE; Keldsen N; Glimelius B; Bjerregaard B; Mejer J; Larsen FO; Pfeiffer P
    Ann Oncol; 2010 Jan; 21(1):87-91. PubMed ID: 19622596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome wide association study to identify predictors for severe skin toxicity in colorectal cancer patients treated with cetuximab.
    Baas J; Krens L; Bohringer S; Mol L; Punt C; Guchelaar HJ; Gelderblom H
    PLoS One; 2018; 13(12):e0208080. PubMed ID: 30557370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial.
    Madi A; Fisher D; Wilson RH; Adams RA; Meade AM; Kenny SL; Nichols LL; Seymour MT; Wasan H; Kaplan R; Maughan TS;
    Br J Cancer; 2012 Sep; 107(7):1037-43. PubMed ID: 22935584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer.
    Ducreux M; Bennouna J; Hebbar M; Ychou M; Lledo G; Conroy T; Adenis A; Faroux R; Rebischung C; Bergougnoux L; Kockler L; Douillard JY;
    Int J Cancer; 2011 Feb; 128(3):682-90. PubMed ID: 20473862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.